Igor Aurer, MD, Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Croatia, discusses new treatment approaches in Hodgkin lymphoma.
The approval of brentuximab vedotin for Hodgkin lymphoma was significant and there is now mature data that further confirms its longterm benefit, said Aurer. It is being investigated in combination with other agents and seems to be active without any increase in toxicity.
Another class of agents that has been shown to be very active and very tolerable in Hodgkin lymphoma is checkpoint inhibitors, said Aurer.
PD-1 blockers have the potential to restore immunological sensitivity to Hodgkin lymphoma and enable host T-cells to attack and destroy tumor cells. We will still need to wait longer to get data regarding combination in this setting, said Aurer.